Semaglutide and cardiovascular risk
Semaglutide and cardiovascular risk
Wegovy, the SELECT trial and cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity.
Overview
What the FDA cardiovascular indication for Wegovy means, what SELECT found and how semaglutide fits into comprehensive risk reduction.
Key clinical points
Use the correct product
Wegovy, Ozempic and Rybelsus all contain semaglutide but have different formulations, doses and approved indications.
Individualize treatment
Dose decisions depend on indication, tolerability, response, medical history and the current FDA-approved label.
Support nutrition
Lower appetite can reduce protein, fluid and micronutrient intake unless nutrition is planned deliberately.
Plan for the long term
Obesity is chronic, and discontinuation commonly leads to renewed appetite and weight regain.
The SELECT cardiovascular-outcomes evidence
Wegovy injection is FDA-approved to reduce the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight. The approval was based on a large randomized trial of more than 17,600 participants without diabetes.
Major cardiovascular events occurred in 6.5% of participants assigned semaglutide and 8.0% assigned placebo over the study period. This was a relative risk reduction; individual benefit depends on baseline cardiovascular risk and continued standard care.
What the indication means—and does not mean
Established disease
The cardiovascular indication applies to selected adults who already have established cardiovascular disease and overweight or obesity.
Not a substitute
Semaglutide does not replace blood-pressure care, cholesterol treatment, antiplatelet therapy, smoking cessation or emergency evaluation.
Broader improvements
Weight, waist circumference, glucose, blood pressure and inflammatory or lipid markers may improve, but response varies.
Shared decision
Benefits must be weighed against gastrointestinal effects, gallbladder and pancreatic concerns, eye disease in diabetes and other label warnings.
A comprehensive cardiovascular plan
- Know blood pressure, lipid profile, blood glucose and smoking status.
- Continue cardiology and primary-care treatment.
- Build aerobic and resistance activity gradually when medically cleared.
- Favor nutrient-dense foods and limit highly processed foods, excess sodium and added sugar.
- Evaluate sleep apnea, which is associated with cardiometabolic risk.
- Seek emergency care for symptoms of heart attack or stroke.
How W8MD can help
W8MD physicians and clinicians evaluate weight history, medications, nutrition, body composition, metabolic risk factors and sleep-related barriers before recommending an individualized plan. Available services may include medical weight loss, GLP-1 treatment evaluation, established oral medications, nutrition planning, sleep-apnea care and long-term maintenance support.
When an FDA-approved medication is appropriate and insurance coverage exists, W8MD can review benefits and assist with prior-authorization documentation. Coverage and approval are determined by the health plan.
For semaglutide care, W8MD may monitor response, tolerability, hydration, nutrition, body composition and relevant laboratory findings. The team can also discuss alternatives when a product is not appropriate, tolerated, covered or available.
Frequently asked questions
Is Wegovy approved to prevent a first heart attack in everyone with obesity?
No. The FDA cardiovascular indication is for adults with established cardiovascular disease and overweight or obesity.
Should cardiac medications be stopped after weight loss?
No medication should be stopped without the treating clinician. Risk-factor medicines may still be necessary.
Does Ozempic have the same indication?
Ozempic has product-specific diabetes and cardiovascular indications. Wegovy’s obesity-related cardiovascular indication is distinct.
Authoritative sources
Request a W8MD consultation
W8MD Weight Loss, Sleep & MedSpa provides physician-supervised care in Brooklyn, New York and Northeast Philadelphia. Telehealth may be available for eligible patients based on location and applicable requirements.
Contact W8MD
